Publications

Below there is a detailed list of all the publications published by the EDITOR project, as well as some related publications.

Project’s publications

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Garcia-Gomez A, Li T, de la Calle-Fabregat C et al.  NATURE COMMUNICATIONS. 2021 Jan 18;12(1):421. PubMed link

Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data. Sandmann S, O de Graaf A, Tobiasson M et al.  JOURNAL OF MOLECULAR DIAGNOSIS. 2021 Mar;23(3):347-357. PubMed link

Atomic-Level Mechanism of Pre-mRNA Splicing in Health and Disease. Borišek J, Casalino L, Saltalamacchia A et al.  ACCOUNTS OF CHEMICAL RESEARCH. 2021 Jan 5;54(1):144-154. PubMed link

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Vilarrasa-Blasi R, Soler-Vila P, Verdaguer-Dot N et al.  NATURE COMMUNICATIONS. 2021 Jan 28;12(1):651. PubMed link

Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Valcárcel LV, Amundarain A, Kulis M et al.  LEUKEMIA. 2021 Oct;35(10):3012-3016. PubMed link

Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Vilarrasa-Blasi R, Verdaguer-Dot N, Belver L et al.  LEUKEMIA. 2021 Aug 28 Online ahead of print. PubMed link

The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma. Carrasco-León A, Amundarain A, Gómez-Echarte N et al.  CANCERS. 2021 Apr 20;13(8):1976. PubMed link

Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Carrasco-Leon A, Ezponda T, Meydan C et al.  LEUKEMIA. 2021 May;35(5):1438-1450. PubMed link

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Garcia-Gomez A, Li T, de la Calle-Fabregat C, Rodríguez-Ubreva J et al.  NATURE COMMUNICATIONS. 2021 Jan 18;12(1):421. PubMed link

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Tsaknakis G, Gallì A, Papadakis S et al.  BLOOD. 2021 Oct 7;138(14):1249-1257. PubMed link

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Zanotti R, Bonifacio M, Lucchini G et al.  LEUKEMIA. 2021 Sep 20 Online ahead of print. PubMed link

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. van Zeventer IA, de Graaf AO, van der Klauw MM et al.  BLOOD ADVANCES. 2021 Sep 14;5(17):3266-3278. PubMed link

ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. Beauchamp EM, Leventhal M, Bernard E et al.  BLOOD CANCER DISCOVERY. 2021 Sep;2(5):500-517. PubMed link

Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95 -mutated neoplasms. Todisco G, Creignou M, Gallì A et al.  LEUKEMIA. 2021 Aug;35(8):2371-2381. PubMed link

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Balliu M, Calabresi L, Bartalucci N et al.  BLOOD ADVANCES. 2021 Apr 27;5(8):2184-2195. PubMed link

Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Genuardi E, Klous P, Mantoan B et al.  HEMATOLOGICAL ONCOLOGY. 2021 Aug;39(3):293-303. PubMed link

Application of the Euro Clonality next-generation sequencing- based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. Genuardi E, Romano G, Beccuti M et al.  BRITISH JOURNAL OF HAEMATOLOGY. 2021 Jul;194(2):378-381. PubMed link

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Palladini G, Paiva B, Wechalekar A et al.  BLOOD CANCER JOURNAL. 2021 Feb 16;11(2):34. PubMed link

Waldenström’s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. Askari E, Rodriguez S, García-Sanz R. JOURNAL OF BLOOD  MEDICINE. 2021 Aug 30;12:795-807. PubMed link

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma. Goicoechea I, Puig N, Cedena MT. et al. BLOOD. 2021 Jan 7;137(1):49-60. PubMed link

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Cuenca I, Alameda D, Sanchez-Vega B. et al. LEUKEMIA. 2021 Jan;35(1):245-249. PubMed link

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Raquel Ordoñez, Marta Kulis, Nuria Russiñol et al. GENOME RESEARCH. 2020 Sep;30(9):1217-1227. PubMed link

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Garcés JJ, Bretones G, Burgos L. et al.  LEUKEMIA. 2020 Nov;34(11):3007-3018. PubMed link

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Perez C, Botta C, Zabaleta A. et al. BLOOD. Jul 9;136(2):199-209 (2020). PubMed link

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Maia C, Puig N, Cedena MT. et al. BLOOD. Jun 25;135(26):2375-2387 (2020). PubMed link

Characterization of freshly isolated mesenchymal stromal cells from healthy and multiple myeloma bone marrow: transcriptional modulation of the microenvironment. Alameda D, Saez B, Lara-Astiaso D. et al. HAEMATOLOGICA. 2020 Sep 1;105(9):e470-473. PubMed link

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Paiva B, Puig N, Cedena MT. et al. JOURNAL OF CLINICAL ONCOLOGY Mar 10; 38(8):784-792 (2020). PubMed link

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Duran-Ferrer M, Clot G. et al. NATURE CANCER. 2020 Nov;1(11):1066-1081. PubMed link

AML through the prism of molecular genetics. Charrot S, Armes H, Rio-Machin A, Fitzgibbon J. HAEMATOLOGICA. 2020 Jan;188(1):49-62. PubMed link

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Garcés JJ, Simicek M, Vicari M et al. LEUKEMIA. 2020 Feb;34(2):589-603. PubMed link

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype – A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Malcovati L, Stevenson K, Papaemmanuil E et al. BLOOD. 2020 Jul 9;136(2):157-170. PubMed link

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Rio-Machin A, Vulliamy T, Hug N et al. NATURE COMMUNICATIONS. 2020 Feb 25;11(1):1044. PubMed link

Genetic timestamping of plasma cells in vivo reveals tissue-specific homeostatic population turnover. Xu A-Q, Barbosa RR, Calado D. ELIFE. 2020 Nov 2;9:e59850. PubMed link

Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib. Sevilla-Movilla S, Arellano-Sánchez N, Martínez-Moreno M et al. JOURNAL OF PATHOLOGY. 2020 Sep;252(1):29-40. PubMed link

Endogenous retroelement activation by epigenetic therapy reverses the Warburg effect and elicits mitochondrial-mediated cancer cell death. Fresquet V, Garcia-Barchino MJ, Larrayoz MJ et al. CANCER DISCOVERY. 2020 Sep;252(1):29-40. PubMed link

Future Perspectives.  Dispenzieri A, Merlini G. HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA. 2020 Dec;34(6):1205-1214. PubMed link

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.  Milani P, Basset M, Nuvolone M et al. BLOOD CANCER JOURNAL. 2020 Sep 1;10(8):90. PubMed link

Redirecting proteoxicityNuvolone M, Merlini G. LEUKEMIA. 2020 Dec;34(12):3109-3110. PubMed link

Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.  Basset M, Nuvolone M, Palladini G, Merlini G. EXPERT REVIEW OF HEMATOLOGY. 2020 Sep;13(9):1003-1015. PubMed link

Treating Protein Misfolding Diseases: TherapeuticSuccesses Against Systemic Amyloidoses.  Nevone A, Merlini G, Nuvolone M. FRONTIERS IN PHARMACOLOGY. 2020 Jul 10;11:1024. PubMed link

Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.  Milani P, Sharpley F, Schönland SO et al. AMYLOID. 2020 Dec;27(4):231-236. PubMed link

High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.  Milani P, Fazio F, Basset M et al. AMERICAN JOURNAL OF HEMATOLOGY. 2020 Aug;95(8):900-905. PubMed link

CRAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.  Coltro G, Rotunno G, Mannelli L et al. BLOOD ADVANCES. 2020 Aug 11;4(15):3677-3687. PubMed link

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis.  Zingariello M, Rosti V, Vannucchi AM et al. FRONTIERS IN ONCOLOGY. 2020 Nov 16;10:584541. PubMed link

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Puig N, Paiva B, Lasa M et al.  LEUKEMIA. 2019 May;33(5):1256-1267. PubMed link

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Moreno L, Perez C, Zabaleta A et al.  CLINICAL CANCER RESEARCH. 2019 May 15;25(10):3176-3187. PubMed link

Related publications

Engineering a Humanised Niche to Support Human Haematopoiesis in Mice: Novel Opportunities in Modelling Cancer. Sanchez-Herrero A, Calvo IA, Flandes-Iparraguirre M et al. CANCERS (BASEL).  Aug 6 (2020). PubMed link

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Rio-Machin, A., Vulliamy, T., Hug, N. et al. NATURE COMMUNICATIONS 11 (1): 1044 (2020). PubMed link

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, Onecha E, Lecumberri R, Prosper F, Ocio EM, González ME, García de Coca A, De La Rubia J, Gironella M, Palomera L, Oriol A, Casanova M, Cabañas V, Taboada F, Pérez-Montaña A, De Arriba F, Puig N, Carreño-Tarragona G, Barrio S, Enrique de la Puerta J, Ramirez-Payer A, Krsnik I, Bargay JJ, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B, Lopez JM. LEUKEMIA Mar 19 (2020). PubMed link

Characterization of freshly isolated mesenchymal stromal cells from healthy and multiple myeloma bone marrow: transcriptional modulation of the microenvironment. Alameda D, Saez B, Lara-Astiaso D, Sarvide S, Lasa M, Alignani D, Rodriguez I, Garate S, Vilas A, Paiva B, Alfonso-Olmos M, Lamo de Espinosa JM, Prosper F, San Miguel JF, Maiso P. HAEMATOLOGICA Jan 23 (2020). PubMed link

Follicular Lymphoma. Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J. NATURE REVIEWS DISEASE  PRIMERS 5 (1): 83 (2019). PubMed link

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. JOURNAL OF CLINICAL ONCOLOGY 38 (8): 784 (2019). PubMed link

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, Alignani D, Calasanz MJ, Growkova K, Goicoechea I, Agirre X, Pour L, Prosper F, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Perez-Montaña A, Garate S, Blanco L, Lasa M, Maiso P, Flores-Montero J, Sanoja-Flores L, Chyra Z, Vdovin A, Sevcikova T, Jelinek T, Botta C, El Omri H, Keats J, Orfao A, Hajek R, San-Miguel JF, Paiva B. LEUKEMIA 34 (2): 589 (2019). PubMed link

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B. CLINICAL CANCER RESEARCH 25 (19): 3176 (2019). PubMed link

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF. LEUKEMIA 33 (5): 1256 (2019). PubMed link